HCLS1 Knockout HAP1 Polyclonal Cells are a population of human HAP1 cells with CRISPR/Cas9-mediated disruption of the HCLS1 gene, generating a loss-of-function model for functional genomics. This polyclonal knockout product provides a heterogeneous pool of edited cells, avoiding clonal selection bottlenecks and enabling robust investigation of HCLS1-dependent processes in hematopoietic biology.
The HAP1 host line is a near-haploid, adherent cell line derived from KBM-7 chronic myelogenous leukemia cells. Its near-haploid karyotype minimizes allelic complexity, making it ideal for genetic knockout screens and functional studies. The hematopoietic origin retains features relevant to blood cell signaling, cytoskeletal regulation, and oncogenic mechanisms.
HCLS1 encodes an adaptor protein linking antigen receptor signaling to actin cytoskeletal remodeling. Upon BCR/TCR stimulation, HCLS1 is phosphorylated by Lyn and Syk kinases, then recruits Vav1 and the Arp2/3 complex, along with cortactin and WASp, to drive localized actin polymerization. This facilitates immune synapse formation, adhesion, and migration. Phosphorylated HCLS1 serves as a scaffold for these effectors, promoting actin nucleation and branching, critical for immune cell function. Additionally, it couples to transcriptional outputs via NF-??B and AP-1, coordinating cytoskeletal changes with gene expression.
In the HAP1 hematopoietic context, HCLS1 knockout disrupts antigen receptor-proximal signaling and actin dynamics. The near-haploid genome ensures complete loss of function from a single edit, allowing clear dissection of HCLS1??s role upstream of Vav1 and Arp2/3 in processes like immune synapse stabilization and B-cell spreading. The CML origin also makes this model relevant for studying HCLS1 in leukemia, where aberrant signaling and cytoskeletal dysregulation occur.
Key applications include functional studies of B- and T-cell signaling, screening for regulators of immune activation, and validation of genetic interactions in lymphoma and immunodeficiency. Experimental approaches encompass western blotting for HCLS1 and phospho-HCLS1, immunofluorescence for actin architecture, flow cytometry for activation markers, and cell migration assays. Co-immunoprecipitation and phospho-signaling analyses further probe interaction networks and kinase activity. This polyclonal knockout population is suitable for both arrayed and pooled screening in drug discovery targeting hematopoietic cancers and immune disorders. For further information, contact Ascent Research.
